Management of Dyslipidaemia 2017 (5th Edition)
Dyslipidaemia remains a significant problem in Malaysia, with the National Health and Morbidity survey in 2015 reporting an estimated 47% of the adult population having hypercholesterolaemia. In the main, dyslipidaemia is asymptomatic but its associations with serious vascular conditions such as acute myocardial infarction and stroke is well known.
The previous edition of the National Clinical Practice Guidelines (CPGs) were launched in 2011. Since then, the evidence base on this subject has grown and new treatments now available. In addition, more clinical information on dyslipidaemia has emerged from Malaysia and in region. Therefore, this edition, which is the 5th Edition of the CPG on the Management of Dyslipidaemia, is timely.
Accessing this CPG, and others endorsed by the Ministry of Health, by healthcare providers is now easier, with the advent of modern telecommunications – downloading a soft copy of this CPG should be a seamless affair. I anticipate the readership of this and other such CPGs to grow and the information provided be useful for healthcare providers in their day to day management of patients.
I would like to congratulate the multidisciplinary team for working together for many months to produce this CPG. Members of the this CPG Expert Panel consist of experts from both the private and public sectors, from primary to tertiary care centres, and from across the country. Under the capable and enthusiastic leadership of Dr Robaayah Zambahari, supported by Dr Jeyamalar Rajadurai, the Expert Panel regularly met to ensure the most recent and relevant information are incorporated into this CPG. I also thank members of the Panel of External Reviewers for their efforts.
Finally, I hope elements of this CPG will be put into practice on a daily basis, to tackle the problem of dyslipidaemia in this country, and eventually result in a drop in mortality and morbidity associated with vascular disease. I am sure this 5th Edition of the CPG on the Management of Dyslipidaemia (2017) will go a long way towards achieving this.
Datuk Dr. Noor Hisham Bin Abdullah
Director-General of Health Malaysia
Ministry of Health Malaysia
Statement of intent:
This guideline was developed to be a guide for best clinical practice in the management of dyslipidaemia, based on the best available evidence at the time of development. Specific attempts were made to use local data and publications to ensure local relevance. Adherence to this guideline does not necessarily lead to the best clinical outcome in individual patient care. Every health care provider is responsible for the management of his/her unique patient based on the clinical presentation and management options available locally.
Review of the Guideline:
This guideline is issued in 2017 and will be reviewed in about 5 years or earlier if important new evidence becomes available.
Download the full document below: